

Corrected V2: Respiratory Pathogen Panel to now include COVID-19 and Bordetella parapertussis

Date: July 24, 2020

This is a second correction to the interface build info that was sent 7/23/20. Please see correct build info below. We apologize for the inconvenience.

Dear Regional Pathology Services Clients,

We are very excited to announce that effective July 16, 2020 we have began offering the Respiratory Pathogen Panel that now includes the SARS CoV-2 causing COVID19.

The BioFire respiratory panel 2.1 (RP2.1) is an FDA-approved multiplex PCR panel that can be used to identify 22 bacterial and viral pathogens. In comparison to our current respiratory panel, this panel detects SARS CoV-2 causing COVID19 and *Bordetella parapertussis*. However, due to the limited quantity of panels available, the RP2.1 should not be used as a primary COVID19 diagnostic. Instead, the RP2.1 should be reserved for use in populations where knowledge of specific viral pathogens has clinical impact (i.e. RSV or Parainfluenza in stem cell transplant patient) or there is significant diagnostic uncertainty (i.e. atypical pneumonia not responding to antibiotics). Note this diagnostic approach may change during influenza season depending on a variety of factors including the development of other platforms that rapidly identify both influenza and SARS CoV-2.

Guidelines for RP2.1 use during the COVID19 pandemic:

- Patients with symptoms concerning for COVID-19 should be tested for SARS-CoV-2 using our current COVID-19 PCR test (Test code: COV19)
- For patients where there is strong suspicion for other respiratory pathogens or where COVID testing is negative the RP2.1 may be considered
- The RPP is adequately sensitive for SARS-CoV-2 and can be used in the process of ruling out COVID19 if needed, although testing using the current SARS-CoV-2 testing platform (COV19) is strongly preferred. The determination of the need for 1 or 2 COVID tests should follow current protocols.
- Patients who have been tested with the RPP should not be retested for at least 7 days.
- Asymptomatic patients should **NOT** be tested using the RPP including pre-procedural and admission-based screening. Screening for COVID-19 should be done using the current SARS-CoV-2 tests (COV19).

Source: Nasopharyngeal swab in viral transport media. Note: BAL is no longer an accepted source for the respiratory panel.

Test Name: Respiratory pathogen panel by PCR (viral/bacterial)

Test Code: RESPP

Below are the pathogens included in the panel and the Interface Build Info. Please note that the CPT code has changed from PLA 0099U to PLA 0202U. Client fees remain the same. New pathogens added and new result codes are highlighted in the table below.



| DECLONIAL | PATHOLOGY SERVICES |
|-----------|--------------------|
| | |

| OrderCo de | <u>OrderName</u> | ResultCode | ResultName | ResultUn its | LOIN C | <u>CPT</u> |
|---------------|------------------------|------------|------------------------|-----------------|-------------|------------|
| <u>ue</u> | | | | 115 | <u>C</u> | |
| RESPP | RESP PATH PANEL PCR | ADEN | ADENOVIRUS | | 82160- 3 | 0202 U |
| RESPP | RESP PATH PANEL PCR | CV229E | CORONAVIRUS 229E | | 82163- 7 | |
| RESPP | RESP PATH PANEL PCR | CVHKU1 | CORONAVIRUS HKU1 | | 82161- 1 | |
| RESPP | RESP PATH PANEL PCR | CVNL63 | CORONAVIRUS NL63 | | 82162- 9 | |
| RESPP | RESP PATH PANEL PCR | CVOC43 | CORONAVIRUS OC43 | | 82164- 5 | I |
| RESPP | RESP PATH PANEL PCR | SARSV2 | SARS-CoV-2 | I | 94565- 9 | |
| RESPP | RESP PATH PANEL PCR | НМЕТАР | METAPNEUMOVIRUS | | 82165- 2 | |
| RESPP | RESP PATH PANEL PCR | HRHENT | RHINOVIRUS/ENTEROVIRUS | | 82175- 1 | |
| RESPP | RESP PATH PANEL PCR | IVA | INFLUENZA TYPE A | | 82166- 0 | |
| RESPP | RESP PATH PANEL PCR | IV2009 | INFLU 2009A-H1N1v | | 82168- 6 | |
| RESPP | RESP PATH PANEL PCR | IVAH1 | INFLU A SUBTYPE H1 | | 82167- 8 | |
| RESPP | RESP PATH PANEL PCR | IVAH3 | INFLU A SUBTYPE H3 | | 82169- 4 | |
| RESPP | RESP PATH PANEL PCR | IVB | INFLUENZA TYPE B | | 82170- 2 | |
| RESPP | RESP PATH PANEL PCR | PARAV1 | PARAINFLUENZA 1 | | 82171- 0 | |
| RESPP | RESP PATH PANEL PCR | PARAV2 | PARAINFLUENZA 2 | | 82172- 8 | |
| RESPP | RESP PATH PANEL PCR | PARAV3 | PARAINFLUENZA 3 | | 82173- 6 | |
| RESPP | RESP PATH PANEL PCR | PARAV4 | PARAINFLUENZA 4 | | 82174- 4 | |



| REC | GIONAL PATHOLOGY SERVICES | | | | |
|-------|---------------------------|--------|--------------------------------------|-------------|--|
| RESPP | RESP PATH PANEL PCR | RESYV | RESP SYNCYTIAL VIRUS | 82176- 9 | |
| RESPP | RESP PATH PANEL PCR | BORPER | BORDETELLA PERTUSSIS | 82179- 3 | |
| RESPP | RESP PATH PANEL PCR | BORPAR | BORDETELLA PARAPERTUSSIS (IS1001) | 87621- 9 | |
| RESPP | RESP PATH PANEL PCR | CHLPNE | CHLAMYDOPHILA PNEUMONIAE | 82178- 5 | |
| RESPP | RESP PATH PANEL PCR | MYCPNE | MYCOPLASMA PNEUMONIAE | 82177- 7 | |
| RESPP | RESP PATH PANEL PCR | RVPSRC | Source | 31208- | |
| RESPP | RESP PATH PANEL PCR | RVPCOM | Comment | | |
| RESPP | RESP PATH PANEL PCR | COVTST | First test | 95417- 2 | |
| RESPP | RESP PATH PANEL PCR | COVEMP | Healthcare employee | 95418- 0 | |
| RESPP | RESP PATH PANEL PCR | COVSYM | Symptomatic per CDC | 95419- 8 | |
| RESPP | RESP PATH PANEL PCR | COVDAT | Symptom onset date | 11368- 8 | |
| RESPP | RESP PATH PANEL PCR | COVHOS | Hospitalized | 77974- 4 | |
| RESPP | RESP PATH PANEL PCR | COVICU | In ICU | 95420- 6 | |
| RESPP | RESP PATH PANEL PCR | COVCON | Resident in congregate care setting | 95421- 4 | |
| RESPP | RESP PATH PANEL PCR | COVPRG | Pregnant | 82810- 3 | |
| | | | | | |
| | | | | | |



REGIONAL PATHOLOGY SERVICES any COVID-19 test. This takes effect 8/1/20. We ask that clients please include this information and build in their interfaces if applicable.

AOES:

| Orde r Code | Order Description | AOE Code | AOE Name | Answer | Answer code | Question Type |
|-------------------|------------------------|-------------|-------------------------------------|-----------------|-------------|----------------------|
| RES PP | RESP PATH PANEL PCR | RVPSRC | Source | | | Freetext |
| | | COVTST | First Test | Yes | YES | List |
| | | | | No | NO | |
| | | | | Unknown | U | |
| | | COVEMP | Healthcare employee | Yes | YES | List |
| | | | | No | NO | |
| | | | | Unknown | U | |
| | | COVSYM | Symptomatic per CDC | Yes | YES | List |
| | | | | No | NO | |
| | | | | Unknown | U | |
| | | COVDAT | Symptom onset date | | | Date/Time MMDDYYY |
| | | | | Unknown | U | |
| | | COVHOS | Hospitalized | Yes | YES | List |
| | | | | No | NO | |
| | | | | Unknown | U | |
| | | COVICU | In ICU | Yes | YES | List |
| | | | | No | NO | |
| | | | | Unknown | U | |
| | | COVCON | Resident in congregate care setting | Yes | YES | List |
| | | | | No | NO | |
| | | | | Unknown | U | |
| | | COVPRG | Pregnant | Pregnant | PREG | List |
| | | | | Not Pregnant | NPREG | |
| | | | | Unknown | U | |

If you have any questions please contact client services at 402-559-6420. For technical questions please contact Kathie Rogers, PhD (402-552-3313, katrogers@nebraskamed.com) or Paul D. Fey, PhD (phone 402-559-2122, pager 402-888-5626, email: pfey@unmc.edu)